MAGP-2: An Extracellular Factor Shown to have Pro-Angiogenic Properties in vivo
- Technology Benefits
- Because of its extracellular nature, MAGP-2 can be easily detectable and targetable by antibody-based technologies for example.
- Technology Application
- A target for inhibiting angiogenesis in cancer and other angiogenesis-dependent diseasesStimulating neovascularization by administration of MAGP-2 to ischemic tissues in coronary artery disease, stroke, and delayed wound healingA diagnostic biomarker, especially for cancer
- Detailed Technology Description
- Our scientists have shown the following:In vitro:MAGP-2 is over expressed in human uterine tumor samplesEndothelial cell expression of MAGP-2 increases during angiogenesis in vitroMAGP-2 stimulates angiogenic sprouting in 3-dimensional collagen culturesMAGP-2 increases endothelial cell proliferation and invasion in vitroIn vivo:Significant enhancement of neovascularization when MAGP-2 was implanted into mice through matrigel plugsMAGP-2 increases tumor size and angiogenesis in mice
- Supplementary Information
- Patent Number: US20070243214A1
Application Number: US2006542670A
Inventor: Schiemann, William, P. | Albig, Allan, R.
Priority Date: 30 Sep 2005
Priority Number: US20070243214A1
Application Date: 2 Oct 2006
Publication Date: 18 Oct 2007
IPC Current: A61K003900 | A61K003816 | A61P004300 | C12N000508 | C12Q000118 | C12Q000168
US Class: 4242771 | 43500612 | 435032 | 435375 | 5140133 | 5140193 | 435006 | 514008
Assignee Applicant: National Jewish Medical and Research Centernver
Title: Genes and proteins associated with angiogenesis and uses thereof
Usefulness: Genes and proteins associated with angiogenesis and uses thereof
Summary: The MAGP-2 or its fragment or homologue, or a nucleic acid molecule encoding MAGP-2 or its fragment or homologue, or an agonist or antagonist of MAGP-2, is useful in preparing a medicament for the regulation of angiogenesis (claimed). The method and kit are useful for regulating angiogenesis. The composition and methods are useful for treating diseases, e.g. cancer, ischemia, or stroke.
Novelty: Regulating angiogenesis comprises regulating the expression or biological activity in the cells or tissue of biomarkers
- Industry
- Disease Diagnostic/Treatment
- Sub Category
- Cancer/Tumor
- *Abstract
-
Excessive angiogenesis has emerged as an essential feature of tumor development and appears to be regulated in part by extracellular matrix proteins. Scientists at National Jewish Health have identified an extracellular matrix protein (designated MAGP-2) that acts as a pro-angiogenic agent in vivo.
- *Principal Investigator
-
Name: William Schiemann, Professor
Department: Department of Pediatrics
- Country/Region
- USA
For more information, please click Here
